去甲斑螯素联合索拉菲尼对原发性肝癌的疗效分析  

Effect of norepinephrine combined with sorafenib on primary liver cancer

作　　者：王德华[1] 郑欢伟[1] 王建民[1] 苗同国[1] 董金红[1] 任桂芳[1] WANG Dehua;ZHENG Huanwei;WANG Jianmin;MIAO Tongguo;DONG Jinhong;REN Guifang(Department of Oncology,Fifth Hospital of Shijiazhuang,Shijiazhuang,Hebei 050017,China)

机构地区：[1]河北省石家庄市第五医院肿瘤科,河北石家庄050017

出　　处：《国际检验医学杂志》2020年第13期1608-1611,共4页International Journal of Laboratory Medicine

基　　金：2016年石家庄市科学技术研究与发展指导计划项目(161462273)。

摘　　要：目的探究去甲斑螯素联合索拉菲尼对原发性肝癌(PHC)患者肝肾功能、白细胞水平及肝纤维化的影响。方法回顾性分析2015年1月至2019年8月该院收治的86例不可切除性PHC患者的临床资料,根据治疗方案的不同将86例PHC患者分为研究组和对照组,每组各43例,对照组在经肝动脉化疗栓塞术(TACE)后给予索拉菲尼治疗,研究组在对照组基础上给予去甲斑螯素治疗,两组均连续用药12周。比较两组临床疗效、不良反应、白细胞计数(WBC)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、清蛋白(ALB)、血肌酐(SCr)、血尿素氮(BUN)、肝胆酸(CG)、透明质酸(HA)、三型前胶原肽(PC3)、层粘连蛋白(LN)、肝脏弹性值。结果研究组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗前两组血清ALT、AST、ALB、BUN、SCr、WBC、CG、HA、PC3、LN水平、肝脏弹性值比较,差异无统计学意义(P>0.05);治疗后两组血清ALT、AST、CG、HA、PC3、LN水平、肝脏弹性值较治疗前降低,差异有统计学意义(P<0.05);治疗后两组血清ALB、BUN、SCr、WBC水平较治疗前升高,差异有统计学意义(P<0.05);治疗后研究组血清ALT、AST、CG、HA、PC3、LN水平、肝脏弹性值较对照组降低,差异有统计学意义(P<0.05);治疗后研究组血清ALB、BUN、SCr、WBC水平较对照组升高,差异有统计学意义(P<0.05);研究组总不良反应发生率略高于对照组,差异无统计学意义(P>0.05)。结论去甲斑螯素联合索拉菲尼治疗PHC疗效确切,可有效改善患者肝肾功能,提高机体白细胞水平,减轻肝纤维化的发生,安全性良好,建议推广。Objective To investigate the effects of norepinephrine combined with sorafenib on liver and kidney function,leukocyte level and liver fibrosis in patients with primary hepatocellular carcinoma(PHC).Methods The clinical data of 86 patients with unresectable PHC admitted to the hospital from January 2015 to August 2019 were analyzed retrospectively.Patients were divided into two groups according to the different treatment methods,each with 43 cases.After transcatheter arterial chemoembolization(TACE),the control group received the sorafenib,while the study group received the sorafenib combined with the norepinephrine.Then various indexes were compared after the continuous treatment of 12 weeks,including clinical efficacy,adverse reactions,white blood cells(WBC),alanine aminotransferase(ALT),glutamic oxaloacetic transaminase(AST),albumin(ALB),serum creatinine(SCr),blood urea nitrogen(BUN),cholyglycine(CG),hyaluronic acid(HA),procollagen typeⅢpeptide(PC3),laminin(LN),liver elasticity.Results The total effective rate of the study group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).Serum ALT,AST,ALB,BUN,SCr,WBC,CG,HA,PC3,LN,liver elasticity levels showed no difference between the two groups before treatment(P>0.05).After treatment,serum ALT,AST,CG,HA,PC3,LN,liver elasticity were decreased in both groups,the difference was statistically significant(P<0.05),and were lower in the study group than in the control group,the difference was statistically significant(P<0.05).Meanwhile,serum ALB,BUN,SCr,WBC levels were increased in both groups,the difference was statistically significant(P<0.05),and were higher in the study group than in the control group,the difference was statistically significant(P<0.05).The incidence of total adverse reactions in the study group was slightly higher than that in the control group,with no statistic difference(P>0.05).Conclusion The application of the norepinephrine combined with sorafenib can effectively and safely ameliorate the

关 键 词：去甲斑螯素 索拉菲尼 原发性肝癌 肝功能 肾功能 肝纤维化 

分 类 号：R735.7[医药卫生—肿瘤]